Download free VACC free pdf with questions answers and exam prep VACC Practice test contains a Complete Pool of VACC Questions and Answers and PDF Download checked and substantial including references and clarifications (where material). Our objective to rehearse the VACC Questions and Answers is not just to breeze through the VACC Vascular Access test at first endeavor yet Really Improve Your Knowledge about the VACC test subjects.

Exam Code: VACC Practice exam 2022 by team
VACC Vascular Access
Medical Vascular learner
Killexams : Medical Vascular learner - BingNews Search results Killexams : Medical Vascular learner - BingNews Killexams : Artificial intelligence may predict hospitalization outcomes of geriatric patients with dementia

By using artificial intelligence, Houston Methodist researchers are able to predict hospitalization outcomes of geriatric patients with dementia on the first or second day of hospital admission. This early assessment of outcomes means more timely interventions, better care coordination, more judicious resource allocation, focused care management and timely treatment for these more vulnerable, high-risk patients.

Because geriatric patients with dementia have longer hospital stays and incur higher health care costs than other patients, the team sought to solve this problem by identifying modifiable risk factors and developing an artificial intelligence model that improves patient outcomes, enhances their quality of life and reduces their hospital readmission risk, as well as reducing hospitalization costs once the model is put into practice.

The study, appearing online Sept. 29 in Alzheimer's & Dementia: Translational Research and Clinical Interventions, a journal of the Alzheimer's Association, looked at the hospital records of 8,407 geriatric patients with dementia over 10 years within Houston Methodist's system of eight hospitals, identifying risk factors for poor outcomes among subgroups of patients with different types of dementia that stem from diseases such as Alzheimer's, Parkinson's, vascular dementia and Huntington's, among others.

From this data, the researchers developed a machine learning model to quickly recognize the predictive risk factors and their ranked importance for undesirable hospitalization outcomes early in the course of these patients' hospital stays.

With an accuracy of 95.6%, their model outperformed all other prevalent methods of risk assessment for these multiple types of dementia. The researchers add that none of the other current methods have applied AI to comprehensively predict hospitalization outcomes of elderly patients with dementia in this way nor do they identify specific risk factors that can be modifiable by additional clinical procedures or precautions to reduce the risks.

"The study showed that if we can identify geriatric patients with dementia as soon as they are hospitalized and recognize the significant risk factors, then we can implement some suitable interventions right away," said Eugene C. Lai, M.D., Ph.D., the Robert W. Hervey Distinguished Endowed Chair for Parkinson's Research and Treatment in the Stanley H. Appel Department of Neurology. "By mitigating and correcting the modifiable risk factors for undesirable outcomes immediately, we are able to Improve outcomes and shorten their hospital stays."

Lai, a neurologist, has worked for many years with these patients and wanted to look at ways to better understand how they're managed and their behavior when hospitalized, so clinicians could Improve care and quality of life for them. He approached Stephen T.C. Wong, Ph.D., P.E., a bioinformatics expert and Director of the T. T. and W. F. Chao Center for BRAIN at Houston Methodist, with this idea, because he had previously collaborated with Wong and knew his team had access to the large clinical data warehouse of Houston Methodist patients and the ability to use AI to analyze big data.

Risk factors for each type of dementia were identified, including those amenable to interventions. Top identified hospitalization outcome risk factors included encephalopathy, number of medical problems at admission, pressure ulcers, urinary tract infections, falls, admission source, age, race and anemia, with several overlaps in multi-dementia groups.

Ultimately, the researchers aim to implement mitigation measures to guide clinical interventions to reduce these negative outcomes. Wong says the emerging strategy of applying powerful AI predictions to trigger the implementation of "smart" clinical paths in hospitals is novel and will not only Improve clinical outcomes and patient experiences, but also reduce hospitalization costs.

"Our next steps will be to implement the validated AI model into a mobile app for the ICU and main hospital staff to alert them to geriatric patients with dementia who are at high risk of poor hospitalization outcomes and to guide them on interventional steps to reduce such risks," said Wong, the paper's corresponding author and the John S. Dunn Presidential Distinguished Chair in Biomedical Engineering with the Houston Methodist Research Institute. "We will work with hospital IT to integrate this app seamlessly into EPIC as part of a system-wide implementation for routine clinical use."

He said this will follow the same smart clinical pathway strategy they have been working on to integrate two other novel AI apps his team developed into the EPIC system for routine clinical use to guide interventions that reduce the risk of patient falls with injuries and better assess breast cancer risk to reduce unnecessary biopsies and overdiagnoses.


Risk Factors and Machine Learning Model for Predicting Hospitalization Outcomes in Geriatric Patients with Dementia. Alzheimer's & Dementia: Translational Research and Clinical Interventions. (online Sept. 29, 2022) Xin Wang, Chika F. Ezeana, Lin Wang, Mamta Puppala, Yan-Siang Huang, Yunjie He, Xiaohui Yu, Zheng Yin, Hong Zhao, Eugene C. Lai and Stephen T.C. Wong. DOI:

Mon, 10 Oct 2022 16:15:00 -0500 en text/html
Killexams : 5 things to know about Modern Vascular cannot provide a good user experience to your browser. To use this site and continue to benefit from our journalism and site features, please upgrade to the latest version of Chrome, Edge, Firefox or Safari.

Wed, 05 Oct 2022 13:18:00 -0500 en-US text/html
Killexams : How this inside-out vascular access system simplifies catheter placement
Gabi Niederauer, president and CEO, Bluegrass Vascular Technologies

Gabi Niederauer is president and CEO of Bluegrass Vascular Technologies. [Image courtesy of Bluegrass Vascular Technologies]

Bluegrass Vascular Technologies has figured out a way to make a catheter sheath go inside the body and back out for easy catheter placement in standard access procedures.

The San Antonio, Texas–based company’s Surfacer Inside-Out access system facilitates catheter insertion into the central venous system. The company designed it for use in patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods.

One of the challenges of having a catheter in the body for weeks or months for dialysis or chemotherapy is the risk of blood clots. Thrombosis forms 50% of the time when health providers insert catheters into people for an extended period of time. When thrombosis occurs in a long-term catheter, it can turn into a chronic occlusion — which happens in an estimated 16% of long-term catheters, according to Gabi Niederauer, president and CEO of Bluegrass Vascular Technologies.

Catheter placement can also become difficult if the right internal jugular becomes chronically occluded. When this happens, a doctor may try to gain access to the central venous systems through the outside of the body using a sharp needle. However, this can further complicate the procedure and create a dangerous situation as it often requires blind placement of the needle near the heart and lungs.

“Some doctors try to go in the femoral vein and push a sharp guide wire through the occlusion and snare it on the other side. But what’s most commonly done is if they don’t get access on this side, they just go to the other side,” Niederauer told Medical Design & Outsourcing. “What then happens is for patients who are dependent on catheters like a dialysis patient, they just burn up all of that central vasculature. They essentially cause the same thing to happen on the left side.”

Simplifying catheter placement for safer procedures

Interventional cardiologist Dr. John Gurley developed Bluegrass Vascular’s Surfacer technology to assist in catheter placement. It goes in through the femoral vein and essentially straight through the body to just above the clavicle, where the distance from occlusion to the skin surface is just a few centimeters. There, the doctor can push a sharp wire out to safely pull a catheter in.

The operator navigates the Surfacer from the femoral vein and exits the venous vasculature. A sheath advances over a guidewire to the venous obstruction and provides a conduit for all instruments used during the procedure.

A target goes on the exit area of the body, and the device then pushes through to the obstruction. The system operator adjusts Fluoro, an imaging agent, until the tip of the device is visible within the exit target. Next, the person operating the Surfacer rotates its handle until the target window appears and advances the needle out of the tip.

Bluegrass Vascular Technologies Surfacer Inside-Out

The Surfacer Inside-Out vascular access system [Image courtesy of Bluegrass Vascular Technologies]

The occlusion acts as a stabilizer for the needle wire to pierce the skin at the exit point, and the operator inserts a sheath from the outside in. Finally, there is the removal of the Surfacer removal. Catheter placement takes place through a standard access procedure.

The entire process takes about 20 minutes.

“Essentially, it helps provide vascular access in the right internal jugular for patients whose veins have closed up chronically or permanently. Placement of central venous catheters are done for dialysis access, for nutrition, for chemo, for a number of different reasons. Approximately 6 million central venous catheters are placed each year and about 20% of those are long-term catheters,” Niederauer said.

Bluegrass Vascular Technologies’ Surfacer vascular access device is already in the commercial stage. Health providers have used it in nearly 700 cases. The Surfacer has 13 peer-reviewed publications. It has a CE mark approved, and the FDA granted it a de novo clearance in February 2020. The Centers for Medicare and Medicaid Services assigned the device a New Technology Ambulatory Payment Classification (APC) in September 2021.

Innovative technology creates bumps in the road

One of the main challenges when developing medical devices is the regulatory pathway, and the Surfacer was no exception.

“This is such a novel concept,” Niederauer said. “There’s no other device that enters the body and then comes out of the body, so that was a challenge for the FDA since no other cleared devices operate in that manner.”

The Surfacer went through different divisions of the FDA before it got de novo clearance and the divisions had different expectations on the data set used, she said.

With de novo classifications, the FDA is reviewing devices that are new to the market and do not have substantially equivalent predicates already on the market. The process is typically more rigorous, Niederauer explained.

“Our de novo review by FDA was actually very predictable. We were able to get it approved within their 150 days, where only around 42% of de novo [applications] get reviewed and cleared that quickly,” she said. “So that was a good accomplishment on our end, but then with the pandemic hitting shortly after our FDA approval, we couldn’t really get into hospitals to train physicians and proctor cases. So that slowed down our launch.”

Because the Surfacer System is so unique, another challenge Bluegrass Vascular had to face was obtaining a reimbursement code from CMS. The company applied for a new technology payment classification which would cover the device and the associated procedure the device is used for; however, CMS felt the procedure was already described by the code utilized for the placement of a tunneled catheter.

“It was not just placing a tunnel catheter though, so we had to go back and forth with CMS and that took 19 months, which is a lot longer than 90 days,” Niederauer said.

Focused, direct sales team to drive product adoption

Bluegrass Vascular Technologies has used distributors for its Surfacer since it’s been on the commercial market. But the company is establishing its own sales force and will begin selling the device directly in the U.S. starting Jan. 1, 2023.

The Surfacer technology is new to the medical device industry, so Bluegrass Vascular is still establishing the importance of the device with physicians — and that’s why it is recruiting sales managers with expertise in the vascular space, Niederauer said.

“We believe the type of missionary selling needed to promote a practice-changing device is best done by our own team. The individuals we have hired are passionate about the Surfacer System and the opportunity to promote our life-saving technology. Building out our own direct sales is what’s in store for us in 2023, and I’m really excited about the team we have put together to drive our business forward.”

Tue, 04 Oct 2022 07:32:00 -0500 Danielle Kirsh en-US text/html
Killexams : IRRAS Announces New Educational Webinar Series in Collaboration with the Jacobs Institute and the University of Buffalo Department of Neurosurgery
  • The Jacobs Institute is a one-of-a-kind nonprofit vascular medical technology innovation center located in Buffalo, NY, that operates at the forefront of developing the next generation of medical technology for the treatment of vascular disease.
  • Adnan H. Siddiqui, MD, Ph.D., CEO/CMO of the Jacobs Institute and Director of Neurosurgical Stroke Service for Kaleida Health, will moderate each webinar.            
  • The first series is scheduled for Tuesday, October 25th at 5 pm EST.

STOCKHOLM, Oct. 11, 2022 /PRNewswire/ -- IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the launch of a new educational webinar series, 'Exploring the Impact of IRRAflow's Active Fluid Exchange: Our Early Experience Utilizing IRRAflow for Intracranial Hemorrhage', with the Jacobs Institute.

During each live webinar, Dr. Adnan Siddiqui, Chief Executive Officer and Chief Medical Officer of the Jacobs Institute, will moderate a panel of neurosurgeon experts in a 60-minute interactive discussion around new treatments for intracranial hemorrhage. Physician panelists and courses will vary with each webinar, but the overall subject will focus on the benefits of utilizing IRRAflow's active fluid exchange to quickly and efficiently clear blood from the intraventricular space.

During each episode of the webinar series, Dr. Siddiqui and an esteemed group of expert panelists will discuss the historical shortcomings of traditional treatment for patients with intracranial bleeding and how new technological advances, such as IRRAS' IRRAflow system, expand the options available to treat this challenging patient population. In addition, each physician panelist will discuss their experience incorporating IRRAflow into their clinical practice and share their recently published IRRAflow case reviews and ongoing clinical studies.  

"We are excited to partner with the Jacobs Institute, Dr. Siddiqui, and the University of Buffalo Department of Neurosurgery to bring together leading experts to discuss the evolution in treatment for intracranial bleeding," said Will Martin, President and CEO of IRRAS. "Dr. Siddiqui and his peers in Buffalo are world-renowned for their contribution to advancing innovation in the treatment of stroke, and we feel that this webinar series will create an ideal learning environment where experts share advice with their peers regarding cutting-edge technology, and lessons learned during clinical practice."

The IRRAflow Webinar Series
Title: Exploring the Impact of IRRAflow's Active Fluid Exchange: Our Early Experience Utilizing IRRAflow for Intracranial Hemorrhage
Date: Tuesday, October 25th
Time: 5 pm EST

Moderator: Adnan H. Siddiqui, MD, Ph.D., CEO/CMO of the Jacobs Institute, Professor and Vice Chairman of the University of Buffalo Department of Neurosurgery (UBNS), and Director of Neurosurgical Stroke Service for Kaleida Health


  • Elad Levy, MD, Professor and Chairman of the University of Buffalo Department of Neurosurgery (UBNS), President-Elect of the Congress of Neurological Surgeons, and Co-Director, Gates Stroke Center at Kaleida Health
  • Jason Davies, MD, Ph.D., Director of Cerebrovascular Microsurgery, Director of Endoscopy, Kaleida Health
  • Ryan Hess, MD, Department of Neurosurgery, Jacobs School of Medicine & Biomedical Science
  • Will Martin, President and CEO of IRRAS

Register Here:

About The Jacobs Institute

The Jacobs Institute is a non-profit organization whose mission is to accelerate the development of next-generation technologies in vascular medicine through collisions of physicians, engineers, entrepreneurs, and industry. The JI's vision is to Improve the treatment of vascular disease in Western New York and the world, while fostering local economic development. The JI fosters medical collaboration and innovation through partnerships with the University at Buffalo (UB), Kaleida Health, and industry, to be a fitting tribute to the work and memory of Lawrence D. Jacobs, M.D.

To learn more about the Jacobs Institute, please visit our website at:


IRRAS is a global medical care company focused on delivering innovative medical solutions to Improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit

IRRAS is listed on Nasdaq Stockholm IRRAS.

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on October 11, 2022, at 8:30 (CET).

This information was brought to you by Cision,c3645915

View original content:


© 2022 Benzinga does not provide investment advice. All rights reserved.

Mon, 10 Oct 2022 18:41:00 -0500 text/html
Killexams : Microbot Medical Completes GLP Animal Study for the LIBERTY® Robotic System

Microbot Medical Inc.

HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic System, the first disposable robotic system being developed for endovascular procedures. The study was performed by a team of seasoned Key Opinion Leaders (KOLs) in the endovascular space at a world-class MedTech research laboratory with FDA-required levels of planning, controlling, monitoring, and reporting (GLP standards), using porcine model.

During the GLP animal study, the physicians conducted pre-determined 63 navigations to the targeted sites using the investigational LIBERTY Robotic System and performed an equal number of procedures manually. The performance endpoint of the LIBERTY Robotic System after robotic navigation was successfully completed for 58 out of the 63 targets (92%), while 3 of the targets (4.8%) were not completed due to technical issues and 2 (3.2%) were not completed due to fluoroscopy related issues (non-device related). Post navigation intra-operative selective angiograms of the target vessels showed no definite evidence of acute vascular injury. Follow up angiograms of these vessels in post-procedure day 3 showed normal vessel anatomy without signs of injury. Initial postmortem gross pathology examination of some of the target organs showed preliminary findings, which will be further investigated in the pending histopathology analysis, and potentially an additional pre-clinical study.

In addition to the objective measurements, the performance and usability of the LIBERTY Robotic System were subjectively graded by each of the physicians, with their assessments accounting for features such as ease of navigation to the target, learning curve, and system stability. For the target sites reached, the physicians graded the LIBERTY Robotic system at the highest grade.

“It was a very satisfying experience,” commented Dr. Sebastian Flacke, MD PhD, Professor of Radiology Tufts Medical School, Chief Interventional Radiology, Vice Chair for Research, Lahey Hospital and Medical Center. “It gives you a very precise feeling on what you’re doing with a lot of control.”

"Set-up time is quick,” added Dr. Dmitry J. Rabkin, MD, Ph.D., FSIR, Assistant Chief, Division of Angiography and Interventional Radiology, Department of Radiology, Brigham and Women’s Hospital, after his own experience with LIBERTY during the GLP study. “The learning curve appears to be easy. The all-around experience was very good, delicate and precise.”

“We are very proud and excited of how LIBERTY performed during the GLP animal study,” commented Dr. Eyal Morag, Chief Medical Officer of Microbot. “It was exciting to watch my very esteemed colleagues quickly adapt to performing the procedures robotically, and their success in hitting the targets is a testament to just how accessible LIBERTY is.”

The LIBERTY Robotic System is investigational and has not been cleared by the U.S. Food and Drug Administration for any use, and accordingly it is not commercially available in the United States or in any other market. The Company plans to further support this study with additional pre-clinical and clinical data.

About Microbot Medical Inc.

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at

Safe Harbor

Statements as to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome of its studies to evaluate LIBERTY and other existing and future technologies, uncertainty in the results of pre-clinical studies and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michael Polyviou
EVC Group

Thu, 13 Oct 2022 01:15:00 -0500 en-US text/html
Killexams : Do you know about trouble at Modern Vascular? Here’s how to get in touch cannot provide a good user experience to your browser. To use this site and continue to benefit from our journalism and site features, please upgrade to the latest version of Chrome, Edge, Firefox or Safari.

Wed, 05 Oct 2022 02:20:00 -0500 en-US text/html
Killexams : AI-Enabled Retinal Vasculometry May Help Assess Vascular Health

WEDNESDAY, Oct. 5, 2022 (HealthDay News) — Artificial intelligence (AI)-enabled retinal vasculometry (RV) can help predict circulatory mortality, incident stroke, and myocardial infarction (MI), according to a study published online Oct. 4 in the British Journal of Ophthalmology.

Alicja Regina Rudnicka, M.D., from St. George’s University of London, and colleagues used images from 88,052 U.K. Biobank participants and 7,411 European Prospective Investigation into Cancer (EPIC)-Norfolk participants to examine whether inclusion of AI-enabled RV improves existing risk algorithms for incident stroke, MI, and circulatory mortality. Prognostic models were developed on 65,144 U.K. Biobank participants and validated in 5,862 EPIC-Norfolk participants.

The researchers found that the prediction models for circulatory mortality had optimism-adjusted C-statistics and R2 statistics between 0.75 to 0.77 and 0.33 to 0.44, respectively, in men and women. The addition of RV to Framingham risk scores did not Improve model performance in either cohort for incident stroke and MI. The simpler RV model based on RV, age, smoking status, and medical history performed equally or better than the Framingham risk score.

“The results strengthen the evidence from several similar studies that the retina can be a useful and potentially disruptive source of information for cardiovascular disease risk in personalized medicine,” write the authors of an accompanying editorial. “As the authors discuss, the accessibility of large repositories of retinal photography does make this concept particularly attractive as it enables validation of hypotheses in large, richly phenotyped cohorts.”

Abstract/Full Text


Copyright © 2022 HealthDay. All rights reserved.

Wed, 05 Oct 2022 23:19:00 -0500 en-US text/html
Killexams : AI-enabled imaging of retina's vascular network can predict cardiovascular disease and death

AI-enabled imaging of the retina's network of veins and arteries can accurately predict cardiovascular disease and death, without the need for blood tests or blood pressure measurement, finds research published online in the British Journal of Ophthalmology.

As such, it paves the way for a highly effective, non-invasive screening test for people at medium to high risk of circulatory disease that doesn't have to be done in a clinic, suggest the researchers.

Circulatory diseases, including , , heart failure and stroke, are major causes of ill health and death worldwide, accounting for 1 in 4 UK deaths alone.

While several risk frameworks exist, these aren't always able to accurately identify those who will go on to develop or die of circulatory diseases, say the researchers. Previously published research indicates that the width of the tiny veins and arteries (arterioles and venules) of the retina—the part of the eye that receives and organizes —may provide an accurate early indicator of circulatory disease. But it's not clear whether these findings apply consistently and equally to men and women.

So the researchers developed a fully automated artificial intelligence (AI)- enabled algorithm (QUantitative Analysis of Retinal vessels Topology and siZe, or QUARTZ for short) to develop models to assess the potential of retinal vasculature imaging plus known to predict vascular health and death.

They applied QUARTZ to from 88,052 UK Biobank participants aged 40-69, looking specifically at the width, vessel area, and degree of curviness (tortuosity) of the arterioles and venules in the retina to develop prediction models for stroke, heart attack, and death from circulatory disease.

They subsequently applied these models to the retinal images of 7411 participants, aged 48-92, of the European Prospective Investigation into Cancer (EPIC)-Norfolk study. The performance of QUARTZ was compared with the widely used Framingham Risk Scores framework, both separately and jointly.

The health of all the participants was tracked for an average of 7 to 9 years, during which time there were 327 circulatory disease deaths among 64,144 UK Biobank participants (average age 56) and 201 circulatory deaths among 5862 EPIC-Norfolk participants (average age 67).

In men, arteriolar and venular width, tortuosity, and width variation emerged as important predictors of death from circulatory disease. In women, arteriolar and venular area and width and venular tortuosity and width variation contributed to risk prediction.

The predictive impact of retinal vasculature on circulatory disease interacted with smoking, drugs to treat , and previous heart attack. Overall, these predictive models, based on age, smoking, medical history and retinal vasculature, captured between half and two thirds of circulatory disease deaths in those most at risk.

Retinal vasculature models captured about 5% more cases of stroke in UK Biobank men and 8% more cases in UK Biobank women and 3% more cases among EPIC-Norfolk men most at risk, but nearly 2% fewer cases among EPIC-Norfolk women. Framingham Risk Scores captured more cases of heart attack among those most at risk.

Adding retinal vasculature to Framingham Risk Scores effected only marginal changes in the prediction of stroke or heart attack. But a simpler non-invasive risk score based on age, sex, smoking, medical history and retinal vasculature performed as well as the Framingham Risk Scores, and without the need for blood tests or blood pressure measurement, say the researchers.

They acknowledge that both groups of study participants have healthier lifestyles than other geographically similar middle-aged people, and that most are white. But this is the largest population-based study of retinal vasculature, and the were externally validated in a large number of people, they explain.

Retinal imaging is already common practice in the UK and the U.S., point out the researchers, who conclude, "AI-enabled vasculometry risk prediction is fully automated, low cost, non-invasive and has the potential for reaching a higher proportion of the population in the community because of 'high street' availability and because blood sampling or [blood pressure measurement] are not needed."

They continue, "[Retinal vasculature] is a microvascular marker, hence offers better prediction for circulatory mortality and stroke compared with [heart attack] which is more macrovascular, except perhaps in women.

"In the general population it could be used as a non-contact form of systemic vascular health check, to triage those at medium-high risk of circulatory mortality for further clinical risk assessment and appropriate intervention."

In the UK, for example, it could be included in the primary care NHS Health Check for those aged 41-74, they suggest.

In a linked editorial, Drs. Ify Mordi and Emanuele Trucco of the University of Dundee, Scotland, explain that the use of retinal vasculature changes to inform overall cardiovascular risk is "certainly attractive and intuitive," but is yet to become part of routine clinical practice.

"Using retinal screening in this way would presumably require a significant increase in the number of ophthalmologists or otherwise trained assessors," they suggest, and ask: Which specialty would take on responsibility for preventive treatment and the additional workload: ophthalmologists, cardiologists, or primary care practitioners?

"What is now needed is for ophthalmologists, cardiologists, primary care physicians and computer scientists to work together to design studies to determine whether using this information improves clinical outcome, and, if so, to work with regulatory bodies, scientific societies and healthcare systems to optimize clinical workflows and enable practical implementation in routine practice," they conclude.

More information: Artificial intelligence-enabled retinal vasculometry for prediction of circulatory mortality, myocardial infarction and stroke, British Journal of Ophthalmology (2022). DOI: 10.1136/bjophthalmol-2022-321842

Ify Mordi et al, The eyes as a window to the heart: looking beyond the horizon, British Journal of Ophthalmology (2022). DOI: 10.1136/bjo-2022-322517

Citation: AI-enabled imaging of retina's vascular network can predict cardiovascular disease and death (2022, October 4) retrieved 17 October 2022 from

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Mon, 03 Oct 2022 12:00:00 -0500 en text/html
Killexams : Peripheral Vascular Stents Market to cross USD 5.3 Bn by 2028, Says Future Market Insights

According to the latest market report published by Future Market Insights, titled ‘Peripheral Vascular Stents Market: Global Industry Analysis 2013 – 2021 and Opportunity Assessment 2022 – 2028’, the global peripheral vascular stents market is expected to expand at a CAGR of 6.6% over the forecast period 2022–2028.

FMI estimates that the global market for peripheral vascular stents is to be valued at US$ 2,822.5 Mn in 2022 and is expected to expand at CAGR of 6.6% over 2022–2028, to reach US$ 5,324.1 Mn by 2028 end. Based on product type, the self-expanding stents segment dominated the global peripheral vascular stents market, with over 52.1% value share in 2021.

The segment is expected to grow at above 6.6% CAGR over the forecast period.North America is expected to maintain its dominance in the global market due to regulatory approval of several new products such as drug eluting stents in the U.S., Europe and Japan.

Increasing awareness of peripheral surgeries and prevalence of peripheral artery disease in developing countries such as India and Brazil remains the major factor driving the demand for peripheral vascular stents. Increasing in number end users and growing number of ambulatory surgical centres are the other major factors expected to drive the growth of the global peripheral vascular stents market.

An intravascular stent is a synthetic tubular mesh structure used for permanent implant in graft or native vasculature. A stent is basically designed to provide mechanical radial support after assigning; the support is meant to Improve vessel patency over the life of the device. After the stent is placed in the intended location, it is expanded by a balloon or self-expanding mechanism.

Global Peripheral Vascular Stents Market: Segmental Forecast

The global peripheral vascular stents market has been segmented on the basis of product type, artery type, end user and regions. Globally, the self-expanding stents is expected to be the most attractive segment from the manufacturers’ point of view. Although there is a high demand for drug eluting stents and the segment leads in terms of market volume in the forecast period, high price of drug eluting stents would lead to low revenue contribution of the product type segment. Among all the artery types, high demand of peripheral stents is expected to come from iliac artery segment due to growing prevalence for peripheral artery disease in many countries across the globe.

Request demo PDF Brochure:

Global Peripheral Vascular Stents Market: Regional Analysis

In terms of value, the global peripheral vascular stents market is expected to expand at 6.6% CAGR over the forecast period of 2022–2028. With nearly 48.5% market share, North America dominated in the global peripheral vascular stents market in 2021, partly due to penetration of newly approved drug eluting stents in the U.S. Western Europe is expected to be the second large market globally, with the U.K., Italy, France and Germany being countries with high growth rates. APEJ is expected to be the second large market for peripheral vascular stents, primarily due to improving immunization access and availability of cost-effective surgeries.

Global Peripheral Vascular Stents Market: Competition Tracking

The market for peripheral vascular stents is consolidated with few players contributing over 55% of revenue share. The key players identified in the global market include Medtronic Plc., Becton, Dickinson and Company, Cardinal Health, Inc., B. Braun Melsungen AG, MicroPort Scientific Corporation, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, Abbott Laboratories, W.L. Gore & Associates Inc., and Cook Medical Inc., among others. Acquisition of established products to gain immediate growth is the key strategy adopted by key players in the market.

Market Segmentation:

Peripheral Vascular Stents Market by Product Type:

  • Self-Expanding Stents
  • Balloon-Expanding Stents
  • Covered Stents
  • Drug-Eluting Stents

Peripheral Vascular Stents Market by Artery Type:

  • Carotid Artery
  • Fem-Pop Artery
  • Iliac Artery
  • Infrapop Artery

Peripheral Vascular Stents Market by End User:

  • Hospitals
  • Ambulatory Surgical Centers/Outpatients

Peripheral Vascular Stents Market by Region:

  • North America Peripheral Vascular Stents Market
  • Latin America Peripheral Vascular Stents Market
  • Europe Peripheral Vascular Stents Market
  • East Asia Peripheral Vascular Stents Market
  • South Asia & Pacific Peripheral Vascular Stents Market
  • Middle East & Africa (MEA) Peripheral Vascular Stents Market

Ask for Customization:

Table of Content

  1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

  1. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

  1. Global Peripheral Vascular Stents Market Opportunity Analysis

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

Get In Touch With Our Team For 20% Flat Discount:

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact Us:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705


LinkedIn| Twitter| Blogs

Tue, 11 Oct 2022 21:52:00 -0500 en text/html
Killexams : Clark State diagnostic medical sonography program awarded initial accreditation

Oct. 3—Clark State College's Diagnostic Medical Sonography — Obstetrics and Gynecology program has been awarded initial accreditation by the Commission on Accreditation of Allied Health Education Programs (CAAHEP).

Diagnostic Medical Sonography (DMS), which is the non-invasive use of high frequency sound waves to image anatomic structures within the body, is an abdominal, obstetrics, gynecology and vascular ultrasound program.

Getting this accreditation has been a group effort with many individuals at the college and in the community, said Megan Platfoot, program director.

"Accreditation through CAAHEP will open the door for many more opportunities for our students before and after graduation. I look forward to continuing in my role as program coordinator as we help bring the next generation of sonographers to the workforce," she said.

The recent peer review, conducted by the Joint Review Committee on Education in Diagnostic Medical Sonography (JRC-DMS) and CAAHEP's Board of Directors, recognized the program's compliance with the nationally established accreditation standards.

"The accreditation is external recognition that our DMS program is a quality program for our students and is based on a review of the program as it currently stands," said Rhoda Sommers, dean of health, human and public services.

Sommers added that employers in the region have been supportive of the program, and one of the current students was hired as a "student sonographer" over the summer and has already signed on for a full-time position after graduation in December.

Sonographers are specially trained individuals who work under the close supervision of radiologists, cardiologists and vascular surgeons to help them in determining a medical diagnosis and treatment plan for patients. They are responsible for acquiring diagnostic images of normal and abnormal structures and report findings to the supervising physician.

The program combines didactic and clinical learning experiences that are within the legal scope of responsibility of sonographers. The college accepts a limited number of DMS students per year with technical classes beginning each fall.

After graduation, sonographers may be employed by hospitals, private physician practices, diagnostic imaging centers, research departments and ultrasound machine manufactures.

Platfood said the accreditation ensures the college is providing the best DMS program for its students and the community.

"We will continue to provide the best education for our DMS students and to work closely with our clinical affiliates to help bring more sonographers to the workforce," she said.

For more information, visit the college's website under academics, degrees and certificates, school of health, human and public services, then diagnostic medical sonography.

Mon, 03 Oct 2022 02:13:00 -0500 en-US text/html
VACC exam dump and training guide direct download
Training Exams List